# A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

> **NCT03706365** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 393 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Placebo
- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03706365
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-26
- **Primary completion:** 2024-01-02
- **Final completion:** 2026-06
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706365, "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03706365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*